MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.

MicroRNAs (miRNAs) expression correlates with biological characteristics of both normal cells and cancer cells, but their roles in cancer chemoresistance remain unclear. By microarray analysis, miR-100 was found significantly down-regulated in docetaxel-resistant SPC-A1/DTX cells compared with parental SPC-A1 cells. Ectopic miR-100 expression resensitized SPC-A1/DTX cells to docetaxel by suppression of cell proliferation and induction of cell arrest in G(2)/M phase and apoptosis. Knock-down of Plk1, which was a direct target of miR-100, yielded similar effects as that of ectopic miR-100 expression. The inverse correlation between miR-100 and Plk1 expression was also detected in nude mice SPC-A1/DTX tumor xenografts and clinical lung adenocarcinoma tissues and was proved to be related with the in vivo response to docetaxel. Thus, our results suggested that down-regulation of miR-100 could lead to Plk1 over-expression and eventually to docetaxel chemoresistance of human lung adenocarcinoma.

[1]  K. Strebhardt,et al.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.

[2]  Chun-Yang Fan,et al.  MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel‐induced multidrug resistance , 2011, Head & neck.

[3]  R. Wolthuis,et al.  Polo-like Kinase-1 Is Required for Bipolar Spindle Formation but Is Dispensable for Anaphase Promoting Complex/Cdc20 Activation and Initiation of Cytokinesis* , 2004, Journal of Biological Chemistry.

[4]  John N Weinstein,et al.  MicroRNA expression profiles for the NCI-60 cancer cell panel , 2007, Molecular Cancer Therapeutics.

[5]  Hongtao Yu,et al.  Regulation of APC-Cdc20 by the spindle checkpoint. , 2002, Current opinion in cell biology.

[6]  J. Waldron,et al.  Significance of Plk1 regulation by miR‐100 in human nasopharyngeal cancer , 2009, International journal of cancer.

[7]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[8]  Long-Bang Chen,et al.  Mechanism of drug resistance identified in human lung adenocarcinoma cell line SPC-A1 selected for resistance to docetaxel , 2009 .

[9]  G. Sczakiel,et al.  Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells , 2006, Molecular Cancer Therapeutics.

[10]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[11]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[12]  Yuan Zhang,et al.  The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity , 2009, Journal of experimental & clinical cancer research : CR.

[13]  T. Kwok,et al.  The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. , 2009, Carcinogenesis.

[14]  Kikuya Kato,et al.  Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers , 2007, Breast Cancer Research and Treatment.

[15]  D. Glover,et al.  Polo-like kinases: conservation and divergence in their functions and regulation , 2009, Nature Reviews Molecular Cell Biology.

[16]  Xiang Huang,et al.  The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. , 2009, Cancer biotherapy & radiopharmaceuticals.

[17]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[18]  K. Strebhardt,et al.  Polo-like kinases and oncogenesis , 2005, Oncogene.

[19]  J. Peters,et al.  The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.

[20]  P Wadsworth,et al.  Taxol suppresses dynamics of individual microtubules in living human tumor cells. , 1999, Molecular biology of the cell.

[21]  E. Medrano,et al.  The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity. , 2000, The Journal of investigative dermatology.

[22]  Chaojun Li,et al.  Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo , 2005, Molecular Cancer Therapeutics.

[23]  Jan Ellenberg,et al.  Roles of Polo-like Kinase 1 in the Assembly of Functional Mitotic Spindles , 2004, Current Biology.

[24]  Eva E. Rufino-Palomares,et al.  MicroRNAs as Oncogenes and Tumor Suppressors , 2013 .

[25]  Paul Taylor,et al.  Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance , 2006, Nature chemical biology.

[26]  L. Kastl,et al.  Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells. , 2010, International journal of oncology.

[27]  Feng Bing,et al.  Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1) , 2009, Journal of cellular and molecular medicine.

[28]  E. Nishida,et al.  Plk1 promotes nuclear translocation of human Cdc25C during prophase , 2002, EMBO reports.

[29]  Syed Mohsin,et al.  Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Kam W Leong,et al.  Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. , 2011, ACS nano.

[31]  T. H. Wang,et al.  Paclitaxel‐induced cell death , 2000, Cancer.

[32]  K. Strebhardt,et al.  Rational combinations of siRNAs targeting Plk1 with breast cancer drugs , 2007, Oncogene.

[33]  E. Nishida,et al.  Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase , 2001, Nature.

[34]  I. Brown,et al.  Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells , 2004, Breast Cancer Research.

[35]  K. Lyseng-Williamson,et al.  Docetaxel: a review of its use in metastatic breast cancer. , 2005, Drugs.

[36]  Zhe-Sheng Chen,et al.  Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10) , 2004, Cancer Research.

[37]  Maria Kavallaris,et al.  Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews Cancer.

[38]  Xia Shan,et al.  miR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines , 2010, International journal of cancer.

[39]  D. Lin,et al.  Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[40]  E. Bandrés,et al.  miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to Its Post-transcriptional Thymidilate Synthase Regulation , 2010, Molecular Cancer Therapeutics.

[41]  H. Ackermann,et al.  Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer , 1997, Oncogene.

[42]  E. Nigg,et al.  Cell Cycle Regulation of the Activity and Subcellular Localization of Plk1, a Human Protein Kinase Implicated in Mitotic Spindle Function Finally, Genetic Studies Performed with Fungi and Flies Have Identified Multiple Protein Kinases , 1995 .